Cel-Sci (CVM) vs GridAI Technologies (GRDX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
GridAI Technologies (GRDX) has outperformed Cel-Sci (CVM) over the past year, gaining 20.0% versus a loss of 80.6%. Over five years, CVM leads with a -99.4% price change compared with -100.0% for GRDX. Cel-Sci is the larger company by market cap ($34.3 million vs $34.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CVM | GRDX |
|---|---|---|
| Share price | $1.95 | $4.80 |
| Market cap | $34.30M | $34.23M |
| 1-day change | -8.45% | +16.50% |
| YTD return | -62.93% | +3.00% |
| 1-year return | -80.56% | +20.00% |
| 5-year return | -99.38% | -99.99% |
| EPS (TTM) | $-1.69 | $-5.65 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.39 | $6.93 |
| 52-week low | $0.89 | $1.87 |
| Distance from 52-week high | -81.23% | -30.73% |
| Analyst consensus | none | — |
| Avg. price target upside | +541.03% | — |
| Average volume | 241.50K | 104.68K |
| Shares outstanding | 17.59M | 7.13M |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GRDX has outperformed CVM by 100.6 percentage points over the past year.
About Cel-Sci
CVM stock →CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers.
Healthcare · Biotechnology
About GridAI Technologies
GRDX stock →GridAI Technologies Corp., together with its subsidiaries, designs and develops an artificial intelligence (AI)-driven software and device platform that enables utilities, retailers, and large power users to manage load and distributed energy resources. It also develops Adrulipase, a recombinant lipase enzyme program for the treatment of exocrine pancreatic insufficiency.
Healthcare · Biotechnology
CVM vs GRDX FAQ
Which is bigger, Cel-Sci or GridAI Technologies?
Cel-Sci (CVM) is larger, with a market capitalization of $34.30M compared with $34.23M for GridAI Technologies (GRDX).
Which stock has performed better over the past year, CVM or GRDX?
GRDX returned +20.00% over the past 12 months, compared with -80.56% for CVM (price return, excluding dividends). Past performance does not predict future results.
Are Cel-Sci and GridAI Technologies in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.